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Abstract 16 
Introduction: There is increasing public health concern about the use of anabolic-androgenic 17 
steroids (AAS). Understanding of drug use patterns and practices is important if we are to 18 
develop appropriate risk-reduction interventions. Yet, much remains unclear about the 19 
modes of administration adopted by AAS users. 20 
Methods: We used data from a sub-sample of participants from the Global Drug Survey 2015; 21 
males who reported using injectable or oral AAS in their lifetime (n=1008). 22 
Results: Amongst our sample, approximately one third (35.62%) reported using only 23 
injectable AAS during their lifetime while 35.84% reported using only oral, with less than one 24 
third (28.54%) using both.  25 
Conclusion: These findings suggest there may be a sub-population of individuals who only use 26 
AAS orally. Needle and syringe programs (NSPs) are currently the primary point of health 27 
service engagement; forming the main healthcare environment for medical and harm 28 
reduction advice on steroids. Yet, NSP-based resources are unlikely to reach or be appropriate 29 
to those who do not inject AAS. While there is a general need for health services to be more 30 
accessible when it comes to AAS use, non-injectors are an overlooked group that require 31 
attention. 32 
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1. Introduction 40 
While prevalence surveys suggest lifetime use of anabolic-androgenic steroids (AAS) and 41 
other performance and image enhancing drugs has remained relatively low over time, there 42 
is a growing body of evidence which suggests that the use of these substances is widespread 43 
across the globe (Sagoe, Molde, Andreassen, Torsheim, & Pallesen, 2014). Of particular 44 
concern is the use of AAS among young men (Home Office, 2017). There are various short- 45 
and long-term health harms associated with the use of AAS (Pope et al., 2014); non-prescribed 46 
AAS use is now a recognised public health concern (McVeigh, Evans-Brown, & Bellis, 2012). 47 
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People use AAS orally and via injection. Many individuals use both modes of 48 
administration during the same time-period (cycle) while others may shift from one mode to 49 
the other as their AAS using career progresses. Typically, a person’s first experience using 50 
steroids, regardless of whether mode of administration is oral or injecting, occurs before the 51 
mid- to late-twenties (Begley et al., 2017). The onset of oral consumption of AAS is likely to 52 
be slightly earlier than the onset of the use of injectable substances. In some cases 53 
participating in certain sports (particularly power sports), negative body image and 54 
psychological disorders (e.g. body image disorders) may precede initiation of AAS use (Sagoe, 55 
Andreassen, & Pallesen, 2014). Use of legal sport supplements is also an important predictor 56 
of AAS use within fitness and sport contexts (Boardley & Grix, 2014). Yet, much remains 57 
unclear regarding patterns of AAS use, particularly our knowledge of typical patterns in modes 58 
of AAS administration is limited to specific sub populations of people who use AAS; i.e. oral 59 
or injection first, or simultaneous use of both forms of AAS. Given the link between modes of 60 
administration and health risks associated with AAS use, identifying various patterns of 61 
administration is vital to inform appropriate harm reduction strategies. 62 
Data on AAS use is generally collected via ethnographic work (Christiansen, Vinther, & 63 
Liokaftos, 2017; Underwood, 2017; van de Ven & Mulrooney, 2017) and surveys (Begley et 64 
al., 2017; Zahnow et al., 2018) within needle and syringe programs (NSPs) or 65 
gym/bodybuilding settings. Even with the limited diversity in recruitment samples, variation 66 
in motivations for use and associated health risk behaviours have been identified (van de Ven 67 
et al., 2018; Zahnow et al., 2018). For example,  the use of steroids by older men may be 68 
motivated by anti-ageing aims (Begley et al., 2017; Evans Brown, McVeigh, Perkins, & Bellis, 69 
2012), while police personnel may use AAS for recovery and/or strength purposes 70 
(Hoberman, 2005; Hoberman, 2017).  71 
In contrast to the variability in motivations for using AAS, harm reduction responses 72 
tend to be limited to advice delivered through NSPs. Given individuals who use AAS report 73 
low levels of trust in medical professionals and a reluctance to seek advice or health care from 74 
doctors (Pope, Kanayama, Ionescu-Pioggia, & Hudson, 2004), in regards to their substance 75 
use, it is not surprising that NSPs are noted as their main source of healthcare (e.g. see 76 
Iversen, Hope, & McVeigh, 2016). While NSPs are an important avenue for AAS users to obtain 77 
credible information, these programs are primarily designed to deliver services to injecting 78 
drug users, such as distributing injecting equipment and promoting safe injecting practises. 79 
These services are neither relevant nor attractive to oral users of AAS who do not inject drugs.  80 
As such, a subset of people who use AAS may not be in contact with any form of intervention 81 
or health service provider. A better understanding of different drug use patterns may 82 
therefore provide new insights for planning harm reduction interventions and other public 83 
health initiatives aimed at AAS users. We will therefore explore patterns of AAS use in a 84 
sample of people declaring the use of psychoactive drugs derived from the Global Drug Survey 85 
(GDS). The GDS may be a valuable source to study this drug-using population as data on AAS 86 
use is generally collected via NSPs or gym/bodybuilding settings and this study therefore 87 
provides unique insights into the routes of administration of AAS users. 88 
 89 
2. Methods 90 
Design and Measures 91 
The Global Drug Survey (GDS) is an online, anonymous survey designed to capture in-depth 92 
information about the use of alcohol, tobacco and illicit substances. Since its inception in 2009 93 
the GDS has been conducted annually. It is actively promoted via social networking sites such 94 
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as Twitter, Facebook and Reddit for a period of 1–2 months from its launch in mid-November 95 
each year. Here we use data from the GDS 2015, which was collected between November 96 
2014 and January 2015 from around the world. A total of 89,509 responses were completed 97 
during this time. The GDS survey is self-completed on a self-nominating basis. Other 98 
publications provide details on the design, utility and limitations of the GDS (Barratt et al., 99 
2017). In this study we are interested in a sub-sample of the GDS; males who reported using 100 
injectable or oral AAS in their lifetime (n=1008). Demographics and prevalence of lifetime use 101 
(ever used) of a large number of substances including AAS were collected (see also Zahnow, 102 
McVeigh, Ferris, & Winstock, 2017). In addition, we assessed the average age of first use and 103 
modes of administration including oral, injection or simultaneous use of both forms of AAS.  104 
 105 
Analysis  106 
Data were processed and analysed using Stata 14.0. Continuous variables were summarized 107 
with means and standard deviations while categorical variables were presented in 108 
frequencies and percentages. Student t-tests and Pearson’s chi-square were used to 109 
determine statistical significance between groups. We employed logistic regression analysis 110 
to examine whether the odds of injecting AAS at first use, compared to using AAS orally at 111 
initiation, was associated with demographic characteristics, age first used AAS, prior use of 112 
other psychoactive substances and two indicators of lifestyle behaviours; frequency of 113 
exercise and frequency of binge drinking. We adopted a stepwise method to first estimate 114 
the effects of demographic and drug use variables in Model 1 then assess the impact of adding 115 
two lifestyle variables in Model 2. The impact of the addition of variables was assessed using 116 
the Likelihood Ratio Test. All statistical tests were two tailed and significance level was set at 117 
0.05.  118 
 119 
3. Results 120 
Age of first AAS use  121 
The final analytic cohort comprised 1008 men who reported using AAS and at least one other 122 
psychoactive drug during their lifetime. The average age of the sample was 32.07 years 123 
(SD=11.41). The majority were employed (71.72%) and had engaged in post-secondary school 124 
education (75.8%). The average age of first use of AAS was 23.59 years (SD=9.02). There was 125 
a significant difference in the average age of first AAS between men who initially used AAS 126 
orally compared to those who used by injection; the average age of first use of injectable AAS 127 
was 24.33 years (SD=8.18) indicating that those who injected at first use tended to be older 128 
than those who used orally. The mean age of first use of other psychoactive substances 129 
among men who used steroids was significantly lower than age of first use of AAS (mean=16.9 130 
years, SD=5.22). This reflects age of first drug use reported in the broader male GDS sample 131 
(see Table 1). In terms of other psychoactive substances, the drug used most commonly by 132 
men who used AAS was cannabis (lifetime use: 90.8%), followed by ‘other’ drugs1  (75.06%), 133 
cocaine (61.30%) and/or MDMA (58.56%).  134 
 135 
PLEASE INSERT TABLE 1 HERE 136 
 137 
Modes of Administration 138 
                                                             
1 Other drugs include ketamine, nitrous, GHB, GBL, PCP, hallucinogens, solvents, paint and glue. 
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Amongst our sample of men who use AAS and other psychoactive substances we found a 139 
relatively even split between oral use and intra-muscular injection. Approximately one third 140 
(35.62%) of the men in our sample reported using only injectable AAS during their lifetime 141 
while 35.84% reported using only oral AAS in their lifetime. Less than one third (28.54%) of 142 
the sample reported using both injectable and oral AAS within their lifetime. Of those who 143 
used both modalities the majority reported initial use of both oral and injectable AAS at the 144 
same age (n=179, 69.38%) (see Table 2). Transition between modes of administration, either 145 
from injecting to oral use of AAS or from oral AAS to injecting, occurred among approximately 146 
30% of individuals who reported using both injectable and oral AAS in their lifetime. Amongst 147 
those who did not initiate both oral and injecting AAS at the same time, those who injected 148 
AAS for the first time after they started using AAS orally, took an average of 2.69 years to 149 
adopt the modality while those who started out using injectable AAS took an average of 3.81 150 
years to take up oral use (see Table 2). The difference between time to transition was not 151 
statistically significant (t=-1.26, ns).  152 
 153 
PLEASE INSERT TABLE 2 HERE 154 
 155 
4. Discussion  156 
In this study we found that the majority of AAS users reported using a single mode of 157 
administration for AAS; either oral (35.84%) or injection (35.62%). This was surprising given 158 
the high prevalence of ‘stacking’, polydrug use (Sagoe et al., 2015), and the simultaneous use 159 
of both forms of administration (Begley et al., 2017), noted among the AAS-using population. 160 
While research notes a general reluctance among users of AAS to engage with health services 161 
(Zahnow et al., 2017), NSPs in the UK and Australia report the proportion of clients who use 162 
AAS has increased in recent years. NSPs are a primary source of clean injecting equipment 163 
(e.g. Dunn, Henshaw, & McKay, 2016; McVeigh, Beynon, & Bellis, 2003); other sources include 164 
friends, pharmacies, online and social suppliers (Kimergård, 2015; van de Ven & Mulrooney, 165 
2017). However, here we highlight a group who do not use injection as a mode of 166 
administration. These non-injecting AAS users (oral-only), who also use psychoactive drugs 167 
that are less commonly associated with injecting, are unlikely to engage with NSPs restricting 168 
their access to drug harm minimization and medical advice. This oral-only using group may 169 
therefore never come into contact with harm reduction information, advice and referrals 170 
regarding AAS use or any other form of drug use, or not until a late stage of their drug using 171 
career when/if transition to injecting AAS use occurs. Transition from oral to injecting AAS use 172 
occurs approximately 3 years after the initial experience with AAS. Delayed intervention in 173 
drug abuse is associated with greater adverse effects, dependence and risky patterns of use  174 
(Modesto-Lowe, Petry, & McCartney, 2008; Stockings et al., 2016). While oral-only users are 175 
not exposed to injection-related risks of blood-borne virus, oral AAS use may be associated 176 
with a number of adverse health effects, with liver toxicity particularly being an issue 177 
(Niedfeldt, 2018). It is therefore important for future studies to explore why people engage 178 
in oral-only use (e.g. requires less planning in sourcing equipment) and to explore the barriers 179 
to accessing healthcare services for this specific group.    180 
Furthermore, although bloodborne viruses (BBVs), such as HIV, hepatitis B and 181 
hepatitis C, are an issue of concern among this population (Hope et al., 2013; van de Ven et 182 
al., 2018), AAS users tend to have lower levels of BBVs compared to other psychoactive drug 183 
users. Adding to this, levels of sharing or reuse of injecting equipment, which is a significant 184 
risk factor for BBV transmission, is much lower amongst user amongst this population when 185 
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compared to those injecting psychoactive drugs (Larance, Degenhardt, Copeland, & Dillon, 186 
2008). This is not to say that educating AAS users about safe injection practises is not 187 
important but due to health services being largely delivered through NSPs this seems to be 188 
the only focus of attention. Yet, recent research indicates that AAS users report having other 189 
personal health priorities and needs, such as better access to medical and clinical advice, 190 
general health monitoring, post-cycle therapy and referrals for endocrinologists and 191 
psychologists, that are currently not being met (Griffiths, Henshaw, McKay, & Dunn, 2017; 192 
Kimergård & McVeigh, 2014; Tighe, Dunn, McKay, & Piatkowski, 2017). A wider range of 193 
interventions and health services are therefore needed; not just to ensure that non-injecting 194 
users are reached but also to address the wider range of medical services important to people 195 
who use AAS. 196 
Although NSPs offer services to AAS users, even experienced drug workers report to 197 
have minimal, if no knowledge at all to meet the needs of users (Dunn, McKay, & Iversen, 198 
2014; Kimergård & McVeigh, 2014) and specialised services, such as the SWEAT program in 199 
the UK and the Steroid Education program run by Kay Stanton in Australia, are marginal. In 200 
addition, although strategies to minimize risks associated with the use of AAS - through both 201 
oral and injection modes of administration – have been reported in the last decade (Bates et 202 
al., 2017; Kimergård & McVeigh, 2014), research is yet to establish the merit of these 203 
approaches empirically. The absence of a clear evidence-base has resulted in inconsistent 204 
education and advice for AAS users. Although there is a general need for health services that 205 
target those who use AAS, to be more accessible, engaging and well-informed, non-injectors 206 
face additional barriers to obtaining harm reduction advice from a medical source. We 207 
suggest future research should focus on evaluating, targeted public health strategies that 208 
involve the AAS using community in all of their development. Given that peer-to-peer 209 
information sharing (both online and face-to-face) is high amongst steroid users (Tighe et al., 210 
2017; van de Ven & Mulrooney, 2017), engaging with and involving steroid communities in 211 
designing and implementing harm reduction interventions could prove a fruitful strategy to 212 
spread evidence-based health information on a large scale. Programs focussed on harm 213 
reduction need to go beyond injecting related risks to provide advice on how to use more 214 
safely, recognising adverse effects early, and facilitating engagement with healthcare.  215 
There are several limitations to our study. Firstly, steroid use in our dataset refers to 216 
lifetime drug use with a sample that has a mean age of 32. As such, while many AAS users 217 
only inject or use orally, it may be that throughout their lifetime users will transition to other 218 
modes of administration or simply stop using before adopting an additional mode of 219 
administration. The sample employed in this study is comprised of people who have declared 220 
their use of psychoactive drugs in the GDS and have also stated the use of AAS at some point 221 
in their lifetime. While generalising results to other sub-groups of AAS users such as athletes 222 
and bodybuilders is not warranted, this study provides unique insights into a group of people 223 
using AAS that are typically not studied. The survey seeks participants from across 174 224 
countries worldwide, 58 of which are represented in the AAS using sub-sample employed 225 
here. However, due to small numbers from individual countries we could not control for 226 
international variation in ease of access to oral/injection AAS, culture of drug use and/or drug 227 
policies or legislation.    228 
 229 
Conclusion  230 
The risk of adverse health implications from using AAS depends on various factors; one of 231 
them being the mode of administration. Our data illustrates a population of AAS users who 232 
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tend to stick to one mode of administration - either oral or injectable steroids. Given the 233 
dominant approach to providing services and advice for people who use AAS is through NSPs, 234 
there is a need to better understand the propensity for oral use only and develop avenues for 235 
reaching this sub-population of users. Given that risks associated with AAS use can be reduced 236 
through strategies that are unrelated to safe injecting, such as shorter cycles and limited 237 
dosages and reduction of polypharmacy, it is important to develop strategies to disseminate 238 
this information systematically to AAS users and potential users outside of NSPs.  239 
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